Copyright
©The Author(s) 2017.
World J Nephrol. May 6, 2017; 6(3): 86-99
Published online May 6, 2017. doi: 10.5527/wjn.v6.i3.86
Published online May 6, 2017. doi: 10.5527/wjn.v6.i3.86
Metaanalyses | Baseline renal functions | Procedure/administration route | Compared drugs | Results |
McCullough et al[104] (16 trials) | Both normal GFR and CKD | PTCA (intra-arterial) | Iodixanol (IOCM) vs various LOCM | Iodixanol safer than LOCM, e.p. in patients with CKD or CKD + diabetes mellitus |
Reed et al[23] (16 trials) | Both normal GFR and CKD | PTCA + CT (intra-arterial + intravenous) | Iodixanol (IOCM) vs various LOCM | Overall, no difference. However, iodixanol safer than ioxaglate and iohexol |
Heinrich et al[48] (25 trials) | Both normal GFR and CKD | PTCA + IV urography + CT (intra-arterial + intravenous) | Iodixanol (IOCM) vs various LOCM | Overall, no difference. However, iodixanol safer than iohexol in CKD patients when CM used via intra-arterial route |
From et al[105] (36 trials) | Both normal GFR and CKD | PTCA + CT (intra-arterial + intravenous) | Iodixanol (IOCM) vs various LOCM | Overall, no difference. Iodixanol safer than iohexol |
Eng et al[24] (29 trials) | Both normal GFR and CKD | PTCA + IV urography + CT (intra-arterial + intravenous) | Iodixanol (IOCM) vs various LOCM | Iodixanol slightly safer than LOCM but the lower risk did not exceed a minimally important clinical difference |
- Citation: Ozkok S, Ozkok A. Contrast-induced acute kidney injury: A review of practical points. World J Nephrol 2017; 6(3): 86-99
- URL: https://www.wjgnet.com/2220-6124/full/v6/i3/86.htm
- DOI: https://dx.doi.org/10.5527/wjn.v6.i3.86